Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ahmed Salem, M.D.

Title
Institution
Department
Address

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Hassan SM, Taha AM, Eldahshan OA, Sayed AA, Salem AM. Modulatory effect of Prosopis juliflora leaves on hepatic fibrogenic and fibrolytic alterations induced in rats by thioacetamide. Biomed Pharmacother. 2019 Apr 26; 115:108788. PMID: 31035010.
    Citations:    
  2. Salem AH, Dave N, Marbury T, Hu B, Miles D, Agarwal SK, Bueno OF, Menon RM. Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment. Clin Pharmacokinet. 2019 Apr 05. PMID: 30949874.
    Citations:    
  3. Wei AH, Strickland SA, Hou JZ, Fiedler W, Lin TL, Walter RB, Enjeti A, Tiong IS, Savona M, Lee S, Chyla B, Popovic R, Salem AH, Agarwal S, Xu T, Fakouhi KM, Humerickhouse R, Hong WJ, Hayslip J, Roboz GJ. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. J Clin Oncol. 2019 May 20; 37(15):1277-1284. PMID: 30892988.
    Citations:    
  4. Jones AK, Salem AH, Freise KJ. Power determination during drug development: Is optimizing the sample size based on exposure-response analyses underutilized? CPT Pharmacometrics Syst Pharmacol. 2019 Jan 18. PMID: 30659774.
    Citations:    
  5. El-Din MS, Taha AM, Sayed AA, Salem AM. Ziziphus spina-christi leaves methanolic extract alleviates diethylnitrosamine-induced hepatocellular carcinoma in rats. Biochem Cell Biol. 2019 Jan 03. PMID: 30605366.
    Citations:    
  6. El-Khazragy N, El Sayed N, Salem AM, Hassan NS, Abdelmoeaz AT, Maher AM, Mansy AE. IL-28ß gene polymorphism determines virological response to PEGylated interferon therapy in hepatitis C virus genotype 4 Egyptian patients. J Cell Biochem. 2018 Nov 18. PMID: 30450628.
    Citations:    
  7. El-Khazragy N, Khalifa MM, Salem AM, Swellam M, Hegazy M. Evaluation of Osteopontin and Pokémon genes expression in hepatitis C virus-associated hepatocellular carcinoma. J Cell Biochem. 2018 Nov 11. PMID: 30417409.
    Citations:    
  8. Agarwal SK, Tong B, Bueno OF, Menon RM, Salem AH. Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors. Adv Ther. 2018 Nov; 35(11):2015-2023. PMID: 30264382.
    Citations:    
  9. Lee JS, Roberts A, Juarez D, Vo TT, Bhatt S, Herzog LO, Mallya S, Bellin RJ, Agarwal SK, Salem AH, Xu T, Jia J, Li L, Hanna JR, Davids MS, Fleischman AG, O'Brien S, Lam LT, Leverson JD, Letai A, Schatz JH, Fruman DA. Statins enhance efficacy of venetoclax in blood cancers. Sci Transl Med. 2018 Jun 13; 10(445). PMID: 29899021.
    Citations:    Fields:    
  10. Salem AH, Mietzel T, Brunstermann R, Widmann R. Two-stage anaerobic fermentation process for bio-hydrogen and bio-methane production from pre-treated organic wastes. Bioresour Technol. 2018 Oct; 265:399-406. PMID: 29933187.
    Citations:    
  11. Soliman B, Salem A, Ghazy M, Abu-Shahba N, El Hefnawi M. Bioinformatics functional analysis of let-7a, miR-34a, and miR-199a/b reveals novel insights into immune system pathways and cancer hallmarks for hepatocellular carcinoma. Tumour Biol. 2018 May; 40(5):1010428318773675. PMID: 29775159.
    Citations:    
  12. Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol. 2018 Jul 01; 36(19):1973-1980. PMID: 29715056.
    Citations: 1     Fields:    
  13. Mangal N, Salem AH, Menon RM, Freise KJ. Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: Evaluation of results from 102 clinical trials. Hematol Oncol. 2018 Apr 19. PMID: 29672885.
    Citations:    
  14. Freise KJ, Hu B, Salem AH. Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics. Eur J Clin Pharmacol. 2018 Apr; 74(4):413-421. PMID: 29302721.
    Citations:    
  15. Khella MS, Salem AM, Abdel-Rahman O, Saad AS. The Association Between the FTO rs9939609 Variant and Malignant Pleural Mesothelioma Risk: A Case-Control Study. Genet Test Mol Biomarkers. 2018 Feb; 22(2):79-84. PMID: 29260910.
    Citations:    
  16. Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, Furman RR, Lamanna N, Barr PM, Zhou L, Chyla B, Salem AH, Verdugo M, Humerickhouse RA, Potluri J, Coutre S, Woyach J, Byrd JC. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018 01; 19(1):65-75. PMID: 29246803.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  17. Schimizzi GV, Jin LX, Davidson JT, Krasnick BA, Ethun CG, Pawlik TM, Poultsides G, Tran T, Idrees K, Isom CA, Weber SM, Salem A, Hawkins WG, Strasberg SM, Doyle MB, Chapman WC, Martin RCG, Scoggins C, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, Maithel SK, Fields RC. Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford). 2018 04; 20(4):332-339. PMID: 29169904.
    Citations:    
  18. Chiney MS, Menon RM, Bueno OF, Tong B, Salem AH. Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin. Xenobiotica. 2018 Sep; 48(9):904-910. PMID: 29027832.
    Citations:    
  19. Li M, Dave N, Salem AH, Freise KJ. Model-based meta-analysis of progression-free survival in non-Hodgkin lymphoma patients. Medicine (Baltimore). 2017 Sep; 96(35):e7988. PMID: 28858138.
    Citations:    
  20. Salem AH, Dunbar M, Agarwal SK. Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia. Anticancer Drugs. 2017 09; 28(8):911-914. PMID: 28562380.
    Citations:    
  21. Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, Touzeau C, Punnoose EA, Cordero J, Munasinghe W, Jia J, Salem AH, Freise KJ, Leverson JD, Enschede SH, Ross JA, Maciag PC, Verdugo M, Harrison SJ. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood. 2017 11 30; 130(22):2392-2400. PMID: 28847998.
    Citations:    
  22. Parikh A, Gopalakrishnan S, Freise KJ, Verdugo ME, Menon RM, Mensing S, Salem AH. Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma. Leuk Lymphoma. 2018 04; 59(4):871-879. PMID: 28797193.
    Citations:    
  23. Agarwal SK, Mangal N, Menon RM, Freise KJ, Salem AH. Response Rates as Predictors of Overall Survival: A Meta-Analysis of Acute Myeloid Leukemia Trials. J Cancer. 2017; 8(9):1562-1567. PMID: 28775775.
    Citations:    
  24. Freise KJ, Jones AK, Eckert D, Mensing S, Wong SL, Humerickhouse RA, Awni WM, Salem AH. Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Clin Pharmacokinet. 2017 05; 56(5):515-523. PMID: 27638334.
    Citations:    
  25. Salem AH, Hu B, Freise KJ, Agarwal SK, Sidhu DS, Wong SL. Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers. Clin Drug Investig. 2017 Mar; 37(3):303-309. PMID: 27910036.
    Citations:    
  26. Agarwal SK, DiNardo CD, Potluri J, Dunbar M, Kantarjian HM, Humerickhouse RA, Wong SL, Menon RM, Konopleva MY, Salem AH. Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments. Clin Ther. 2017 Feb; 39(2):359-367. PMID: 28161120.
    Citations:    
  27. Abrol S, Kotrotsou A, Salem A, Zinn PO, Colen RR. Radiomic Phenotyping in Brain Cancer to Unravel Hidden Information in Medical Images. Top Magn Reson Imaging. 2017 Feb; 26(1):43-53. PMID: 28079714.
    Citations:    
  28. Agarwal SK, Salem AH, Danilov AV, Hu B, Puvvada S, Gutierrez M, Chien D, Lewis LD, Wong SL. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma. Br J Clin Pharmacol. 2017 04; 83(4):846-854. PMID: 27859472.
    Citations:    
  29. Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdugo M, Humerickhouse RA, Gordon GB, Gerecitano JF. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol. 2017 Mar 10; 35(8):826-833. PMID: 28095146.
    Citations: 29     Fields:    Translation:Humans
  30. Freise KJ, Shebley M, Salem AH. Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model. J Clin Pharmacol. 2017 06; 57(6):796-804. PMID: 28052338.
    Citations:    
  31. Barile E, Marconi GD, De SK, Baggio C, Gambini L, Salem AF, Kashyap MK, Castro JE, Kipps TJ, Pellecchia M. hBfl-1/hNOXA Interaction Studies Provide New Insights on the Role of Bfl-1 in Cancer Cell Resistance and for the Design of Novel Anticancer Agents. ACS Chem Biol. 2017 02 17; 12(2):444-455. PMID: 28026162.
    Citations:    
  32. Liu H, Michmerhuizen MJ, Lao Y, Wan K, Salem AH, Sawicki J, Serby M, Vaidyanathan S, Wong SL, Agarwal S, Dunbar M, Sydor J, de Morais SM, Lee AJ. Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites. Drug Metab Dispos. 2017 03; 45(3):294-305. PMID: 27993930.
    Citations:    
  33. Freise KJ, Jones AK, Menon RM, Verdugo ME, Humerickhouse RA, Awni WM, Salem AH. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy. Hematol Oncol. 2017 Dec; 35(4):679-684. PMID: 27982454.
    Citations:    
  34. Salem AH, Agarwal SK, Dunbar M, Enschede SL, Humerickhouse RA, Wong SL. Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma. J Clin Pharmacol. 2017 04; 57(4):484-492. PMID: 27558232.
    Citations:    
  35. El-Hamamsy M, Ghali RR, Saad AS, Shaheen SM, Salem AM. FAS and FASL genetic polymorphisms impact on clinical outcome of malignant pleural mesothelioma. Onco Targets Ther. 2016; 9:6857-6863. PMID: 27853379.
    Citations:    
  36. Agarwal SK, Hu B, Chien D, Wong SL, Salem AH. Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study. J Clin Pharmacol. 2016 11; 56(11):1335-1343. PMID: 26953185.
    Citations:    
  37. Salem AH, Agarwal SK, Dunbar M, Nuthalapati S, Chien D, Freise KJ, Wong SL. Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor. J Clin Pharmacol. 2016 11; 56(11):1355-1361. PMID: 27029823.
    Citations:    
  38. Zureikat AH, Postlewait LM, Liu Y, Gillespie TW, Weber SM, Abbott DE, Ahmad SA, Maithel SK, Hogg ME, Zenati M, Cho CS, Salem A, Xia B, Steve J, Nguyen TK, Keshava HB, Chalikonda S, Walsh RM, Talamonti MS, Stocker SJ, Bentrem DJ, Lumpkin S, Kim HJ, Zeh HJ, Kooby DA. A Multi-institutional Comparison of Perioperative Outcomes of Robotic and Open Pancreaticoduodenectomy. Ann Surg. 2016 Oct; 264(4):640-9. PMID: 27433907.
    Citations:    
  39. Bader El Din NG, Farouk S, El-Shenawy R, Ibrahim MK, Dawood RM, Elhady MM, Salem AM, Zayed N, Khairy A, El Awady MK. Tumor necrosis factor-a -G308A polymorphism is associated with liver pathological changes in hepatitis C virus patients. World J Gastroenterol. 2016 Sep 14; 22(34):7767-77. PMID: 27678360.
    Citations:    
  40. Freise KJ, Dunbar M, Jones AK, Hoffman D, Enschede SL, Wong S, Salem AH. Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis. Cancer Chemother Pharmacol. 2016 10; 78(4):847-53. PMID: 27586967.
    Citations:    
  41. Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, Blum W, DiNardo CD, Kadia T, Dunbar M, Kirby R, Falotico N, Leverson J, Humerickhouse R, Mabry M, Stone R, Kantarjian H, Letai A. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discov. 2016 10; 6(10):1106-1117. PMID: 27520294.
    Citations: 53     Fields:    Translation:HumansCTClinical Trials
  42. Salem AM, Mohammaden TF, Ali MAM, Mohamed EA, Hasan HF. Ellagic and ferulic acids alleviate gamma radiation and aluminium chloride-induced oxidative damage. Life Sci. 2016 Sep 01; 160:2-11. PMID: 27436544.
    Citations:    
  43. Jones AK, Freise KJ, Agarwal SK, Humerickhouse RA, Wong SL, Salem AH. Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis. AAPS J. 2016 09; 18(5):1192-202. PMID: 27233802.
    Citations:    
  44. Ahmed HH, Salem AM, Atta HM, Eskandar EF, Farrag AR, Ghazy MA, Salem NA, Aglan HA. Updates in the pathophysiological mechanisms of Parkinson's disease: Emerging role of bone marrow mesenchymal stem cells. World J Stem Cells. 2016 Mar 26; 8(3):106-17. PMID: 27022441.
    Citations:    
  45. Salem A, Noaman E, Kandil E, Badawi A, Mostafa N. Crystal structure and chemotherapeutic efficacy of the novel compound, gallium tetrachloride betaine, against breast cancer using nanotechnology. Tumour Biol. 2016 Aug; 37(8):11025-38. PMID: 26894603.
    Citations:    
  46. Salem AH, Jones AK, Santini-Oliveira M, Taylor GP, Patterson KB, Nilius AM, Klein CE. No Need for Lopinavir Dose Adjustment during Pregnancy: a Population Pharmacokinetic and Exposure-Response Analysis in Pregnant and Nonpregnant HIV-Infected Subjects. Antimicrob Agents Chemother. 2016 01; 60(1):400-8. PMID: 26525798.
    Citations:    
  47. Lim CN, Salem AH. A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients. Clin Pharmacokinet. 2015 Sep; 54(9):963-73. PMID: 25791895.
    Citations:    
  48. Salem AH, Chiu YL, Valdes JM, Nilius AM, Klein CE. A novel ritonavir paediatric powder formulation is bioequivalent to ritonavir oral solution with a similar food effect. Antivir Ther. 2015; 20(4):425-32. PMID: 25573904.
    Citations:    
  49. Renjifo B, van Wyk J, Salem AH, Bow D, Ng J, Norton M. Pharmacokinetic enhancement in HIV antiretroviral therapy: a comparison of ritonavir and cobicistat. AIDS Rev. 2015 Jan-Mar; 17(1):37-46. PMID: 25586481.
    Citations:    
  50. Goglia AG, Delsite R, Luz AN, Shahbazian D, Salem AF, Sundaram RK, Chiaravalli J, Hendrikx PJ, Wilshire JA, Jasin M, Kluger HM, Glickman JF, Powell SN, Bindra RS. Identification of novel radiosensitizers in a high-throughput, cell-based screen for DSB repair inhibitors. Mol Cancer Ther. 2015 Feb; 14(2):326-42. PMID: 25512618.
    Citations:    
  51. Salem AM, Ahmed HH, Atta HM, Ghazy MA, Aglan HA. Potential of bone marrow mesenchymal stem cells in management of Alzheimer's disease in female rats. Cell Biol Int. 2014 Dec; 38(12):1367-83. PMID: 25044885.
    Citations:    
  52. Salem AH, Zhanel GG, Ibrahim SA, Noreddin AM. Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus. Clin Exp Pharmacol Physiol. 2014 Jun; 41(6):437-43. PMID: 24341387.
    Citations:    
  53. Salem AH, Giranda VL, Mostafa NM. Population pharmacokinetic modeling of veliparib (ABT-888) in patients with non-hematologic malignancies. Clin Pharmacokinet. 2014 May; 53(5):479-88. PMID: 24452810.
    Citations:    
  54. Salem AH, Koenig D, Carlson D. Pooled population pharmacokinetic analysis of phase I, II and III studies of linifanib in cancer patients. Clin Pharmacokinet. 2014 Apr; 53(4):347-59. PMID: 24307488.
    Citations:    
  55. Salem AH, Yang J, Graham A, Patnaik A, Holen K, Pradhan R, Xiong H. Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patients. Anticancer Res. 2014 Apr; 34(4):2001-6. PMID: 24692738.
    Citations:    
  56. Salem AM, Ismail S, Zarouk WA, Abdul Baky O, Sayed AA, Abd El-Hamid S, Salem S. Genetic variants of neurotransmitter-related genes and miRNAs in Egyptian autistic patients. ScientificWorldJournal. 2013; 2013:670621. PMID: 24453887.
    Citations:    
  57. Badr S, Salem A, Yuosif AH, Awadallah H, Awed N, Bakr A. Hypoxia inducible factor-1alpha and microvessel density as angiogenic factors in bilharzial and non-bilharzial bladder cancer. Clin Lab. 2013; 59(7-8):805-12. PMID: 24133909.
    Citations:    
  58. Eissa S, Zohny SF, Shehata HH, Hegazy MG, Salem AM, Esmat M. Urinary retinoic acid receptor-ß2 gene promoter methylation and hyaluronidase activity as noninvasive tests for diagnosis of bladder cancer. Clin Biochem. 2012 Apr; 45(6):402-7. PMID: 22286019.
    Citations:    
  59. Holsinger FC, Sweeney AD, Jantharapattana K, Salem A, Weber RS, Chung WY, Lewis CM, Grant DG. The emergence of endoscopic head and neck surgery. Curr Oncol Rep. 2010 May; 12(3):216-22. PMID: 20425082.
    Citations:    
  60. Eissa S, Zohny SF, Swellam M, Mahmoud MH, El-Zayat TM, Salem AM. Comparison of CD44 and cytokeratin 20 mRNA in voided urine samples as diagnostic tools for bladder cancer. Clin Biochem. 2008 Nov; 41(16-17):1335-41. PMID: 18804101.
    Citations:    
  61. Salem AM, Zohny SF, Abd El-Wahab MM, Hamdy R. Predictive value of osteocalcin and beta-CrossLaps in metastatic breast cancer. Clin Biochem. 2007 Nov; 40(16-17):1201-8. PMID: 17889845.
    Citations:    
  62. Eissa S, Salem AM, Zohny SF, Hegazy MG. The diagnostic efficacy of urinary TGF-beta1 and VEGF in bladder cancer: comparison with voided urine cytology. Cancer Biomark. 2007; 3(6):275-85. PMID: 18048965.
    Citations:    
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Salem's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (267)
Explore
_
Co-Authors (4)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.